19 November 2026 · Bucharest · Europe/Bucharest

THE WORLD, in brief

BREAKING Robert Pattinson is officially the next James Bond, Amazon MGM announces

Share this article

Share on Facebook (new tab)

Instagram has no direct website sharing link. This opens your device share menu where supported; Instagram may not appear. Otherwise copy the link. Nothing is posted automatically.

Lifestyle · 07:26 · 2026-11-11

Escitalopram ranks best at preventing depression relapse in study

An analysis published in The Lancet Psychiatry found escitalopram performed best at preventing depression from coming back, in a comparison involving nearly 10,000 people treated for up to a year. Experts say the differences were modest.

Escitalopram ranks best at preventing depression relapse in study
A box of Escitalopram Actavis 5 mg. Photo: Avopasia, CC BY-SA 4.0 (via Wikimedia Commons); cropped and resized. File image.

Escitalopram performed best at preventing patients from relapsing in an analysis, reported by BBC News, of nearly 10,000 people prescribed different antidepressant medicines for up to a year. The work was published in The Lancet Psychiatry.

Two other drugs, agomelatine and duloxetine, came next, while fluoxetine, also known as Prozac, ranked just below them. The analysis looked at previous studies comparing the effectiveness of more than a dozen common antidepressants. The differences found were modest, and experts told the BBC that longer studies are still needed.

Experts stressed that the findings do not mean everyone with severe depression should switch to escitalopram, or that other antidepressants are of no use, because all of the drugs can work and each has its advantages and drawbacks. Patients, they said, should discuss with their doctor which treatment is best for them. Depression has many contributing causes, and treatment can include medicines and talking therapies.

The paper, titled "Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depressive disorder", was led by Paul van Haaren with colleagues including E. G. Ostinelli, according to the journal listing. It is a network meta-analysis: a statistical method that pools the results of many randomised trials and allows treatments to be compared with each other even when they were never tested head to head in the same study.

Because such analyses depend on the quality and design of the original trials, which often differ in length, dose and patient population, the ranking should not be read as definitive, a point also made in the BBC report. Individual factors such as side effects, other illnesses and a patient's previous response to treatment remain decisive when choosing a medicine.

The study also assessed acceptability, meaning how many patients stopped treatment for any reason, which reflects how well a drug is tolerated over many months.

To reduce the risk of relapse, doctors already recommend that people stay on antidepressants for at least six months after a depressive episode ends, and then taper off gradually. The BBC noted that, with the right treatment and support, many people recover, although for some the illness can return.

The photograph published with this article is a file image of an escitalopram pack. The ranking describes a comparison of existing evidence, not a reason to change a prescription without medical advice.


Source: BBC News; The Lancet Psychiatry

← Back to Lifestyle · Home